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1. Introduction 
Chance et al. [l] have recently isolated a nearly 
identical polypeptide from bovine, ovine, porcine 
and human pancreata. These pancreatic polypeptides 
represent the mammalian counterpart of avian 
pancreatic polypeptide (APP) [2,3]. 
Human pancreatic polypeptide (HPP) contains 
36 amino acids and has an approximate molecular 
weight of 4200 [ 11. Immunoassayable HPP is 
present in blood and its levels increase in response 
to food ingestion and insulin-induced hypoglycemia 
[4,51. 
Since a considerable number of peptide hormones 
appear to circulate in blood in multiple immuno- 
reactive forms [6], this work was undertaken to 
examine the behaviour of plasma immunoreactive 
HPP on molecular sieve chromatography. We have 
fractionated the HPP immunoreactivity present in 
plasma of normal subjects, both in the basal state 
and after stimulation of HPP release by insulin- 
induced hypoglycemia. 
2. Methods and materials 
Blood samples were obtained from five healthy, 
young volunteers through an indwelling butterfly 
needle inserted in an antecubital vein. To stimulate 
HPP secretion regular pork insulin (Actrapid) was 
injected i.v. at a dose of 0.1 U/kg. The extractions 
were made in the basal state (after an overnight fast) 
and at 40, 50 and 60 min following administration 
of insulin. Blood specimens were placed in chilled 
tubes containing EDTA and immediately centrifuged 
at 4°C. The plasma was stored at -20°C until used. 
Circulating HPP was fractionated by molecular 
sieve chromatography on Bio Gel Pa30 or Sephadex 
G-l 00 columns (1 X 50 cm). The columns were 
equilibrated and developed in the same diluent 
that was used in the radioimmunoassay. These 
procedures have been described in detail elsewhere [7] 
HPP in plasma and eluates was measured by 
radioimmunoassay employing rabbit anti-HPP 
serum (Lot #615-1054B-248-19), HPP (Lot 
# 615-l 054B-200) as standard, and bovine 
pancreatic polypeptide (BPP) (Lot # 615-D63-188-9) 
for iodination, which was performed with “‘1 by 
the technique of Greenwood et al. [8]. All these 
substances were kindly donated by Dr Ronald E. 
Chance (Lilly Research Laboratories, Eli Lilly Co. 
Indianapolis, USA). 12’I-BPP was purified on 
Bio Gel P-30, and the monoiodinated component 
was subsequently separated by polyacrylamide 
disc-gel electrophoresis. 1251-BPP was also used as 
tracer in the gel filtration studies. Glycine buffer 
(0.2 M), containing 0.25% human serum albumin 
and 1% normal sheep serum (pH 8.8), served as the 
assay diluent. Full details of our assay will be 
described in a later report. 
3. Results 
Filtration on Bio Gel P-30 of basal plasma from 
each of the five subjects revealed the presence of 
three discrete fractions of immunoreactive HPP, as 
expressed in table 1 and illustrated in the represen- 
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Table 1 
HPP-immunoreactive components on Bio Gel P-30 filtration of plasma (3 ml) from 
normal subjects 
Subject no. 
1 Basal 
Post-insulin 
2 Basal 
Post-insulin 
3 Basal 
Post-insulin 
4 Basal 
Post-insulin 
5 Basal 
Post-insulin 
Total HPP 
loaded 
(pgl 
193 
2448 
240 
2430 
369 
3582 
414 
3450 
834 
4800 
HPP-immunoreactive components 
Fraction I Fraction II Fraction III 
(PPl (pgl (pgl 
37 36 45 
83 1779 18 
60 24 69 
72 1194 57 
156 12 189 
237 3939 183 
48 69 62 
81 2310 72 
126 132 18 
92 1731 33 
tative elution profde depicted in fig.1 (upper panel). 
Between 27% and 46% of the recovered immuno- 
reactivity eluted in the void volume of the column, 
concurrently with plasma proteins (fraction I). The 
second peak appeared in the same effluent position 
as that of the 12’I-PP marker and accounted for 
4-48% of the toatal immunoreactivity (fraction II). 
The slowest migrating component (fraction III) was 
eluted slightly earlier than the iodide marker and 
comprised 7-53% of the immunoreactivity of the 
eluates. 
Plasma samples obtained after insulin-induced 
hypoglycemia contained from 6 to 12-fold higher 
concentrations of HPP than basal specimens. When 
these samples were filtered on Bio Gel P-30, 
immunoreactive HPP appeared to be distributed 
in the same three fractions that have been described 
above. However, the increase in total loaded immuno- 
reactivity was recovered mainly in the area of 
fraction II, which, in this condition, represented 
more than 90% of the total (table 1; fig. 1, lower 
panel). 
Finally, to obtain additional information on the 
gel filtration behaviour of fraction I, basal plasma 
was subjected to chromatography on Sephadex G-l 00 
(fig.2). On this gel, 20% of the recovered immuno- 
reactivity eluted in a position which coincided with 
100 
BASAL 
protein 
mg/ml 
3001 POST-INSULIN 4 
eluate dml) 
Fig.1. Chromatographic pattern on Bio Gel P-30 of the HPP 
immunoreactivity present in the plasma of a normal subject. 
The arrows indicate the elution volume of the radioactive 
markers (‘ZSI-insulin: ‘25I-I; “‘I-pancreatic polypeptide: 
‘*‘I-PP; “‘1-glucagon: “‘1-G; ‘2s1). The shaded area 
represents the immunoreactive HPP, and the broken line 
the protein content of the eluates. 
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Fig.2. Chromatographic pattern on Sephadex G-100 of the 
HPP immunoreactivity present in the plasma of a normal 
subject. The arrows indicate the elution volume of the 
radioactive markers (“‘I-pancreatic polypeptide: ‘*‘I-PP; 
‘251). The shaded area represents the immunoreactive HPP, 
and the broken line the protein content of the eluates. 
plasma globulins and the remaining 80% migrated in 
the zone of the 1251-PP marker. While the first peak 
seemed to correspond to fraction I, the second 
component appeared to represent the areas of frac- 
tions II and III which could not be separated by this 
type of gel. 
4. Discussion 
Our results indicate that, at least, three HPP 
immunoreactive fractions are present in plasma of 
normal subjects. In the basal state, each component 
represents roughly one-third of the total immuno- 
reactivity. The elution position of fraction II allows 
to assume that this material is identical to HPP as 
isolated from the pancreas (mol. wt 4200) [ 11. 
Furthermore, an increase in this fraction accounts 
for most of the immunoreactive HPP found after 
stimulation of HPP secretion by insulin-induced 
hypoglycemia. 
The early-eluting component of immunoreactive 
HPP (fraction I) migrates with plasma globulins on 
Sephadex G-100. Therefore, if it represents a discrete 
molecular species its size would be greater than 
100 000 daltons. On the other hand, the molecular 
weight of the smallest component (fraction III) seems 
to be about 1500. The areas of fractions I and III were 
not obviously modified after stimulation of HPP 
secretion. 
The present study does not permit us to define 
further the nature of fractions I and III, although it 
would be tempting to speculate about their possible 
implications in the processes of HPP biosynthesis 
(fraction I) and degradation (fraction III). Very 
little information is available concerning the 
chromatographic pattern of HPP in its tissue of 
origin. Adrian et al. [9] found no evidence of size 
heterogeneity of immunoreactive HPP in pancreatic 
extracts. If this finding is confirmed, it would favour 
the possibility that fraction I contained HPP in 
association with plasma proteins. 
Finally, the occurrence of fractions I and III in 
blood, independently of their significance, should be 
considered when determining basal HPP concentra- 
tions, since both components account for more than 
half of the measured immunoreactivity. 
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